- Poster presentation
- Open Access
MRI scanning by remote control: experience in pediatric cardiovascular disease
© Lohan et al; licensee BioMed Central Ltd. 2010
Published: 21 January 2010
MRI scanning by remote control has recently been described, a technique that holds considerable promise in making expertise in cardiovascular imaging more widely available to centers where performance of such examinations may not otherwise be possible. We describe single-center experience in perhaps the most technically challenging population of all, pediatric patients, for a variety of cardiovascular conditions.
Materials and methods
Cine steady-state free precession (SSFP) acquisitions were designated scores in the 'excellent' range in 83% of series (94/113) and 'good' for the remaining 17% series (19/113). 71% (80/113) of SSFP cine series showed no artifactual degradation, minimal artifact was detected in 28% (32/113), while in only 0.9% (1/113) was moderate artifact noted. With regard to contrast-enhanced MRA, 96.6% of studies were assigned a score in the 'excellent' range (57/59 cases), the remaining 2 studies receiving a score in the 'good' range. Of 1815 evaluable arterial segments, failure of visualization due to technical reasons occurred in only 7 segments (0.4%). 91 segments (5%) showed 'poor' segmental visualization, 243 segments (13.4%) were 'well-defined', while the remaining 1474 segments (81.2%) received an optimal score in the 'excellent' range. Detrimental artifact was noted in 35.6% studies (21/59) during CE-MRA, most commonly occurring as a result of cardiac motion. External validation of MRI findings was facilitated by the availability of 73 complementary imaging examinations and 26 open surgical procedures.
Remotely controlled MRI scanning of pediatric patients as young as 1 day is feasible, producing high-quality examinations in the diagnostic range. This holds the potential to disseminate specialized technical and clinical expertise, regardless of geographic location.
This article is published under license to BioMed Central Ltd.